Skip to main content

Month: December 2020

Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020

VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability data using VASCEPA loading doseVASCEPA administration resulted in a significant 52% reduction of the total patient-reported symptom outcome prevalence score as compared to a 24% reduction in the usual care groupLarger follow-on clinical studies have commenced of VASCEPA as a therapeutic option in COVID-19 settings, anticipated to be completed in 2021Amarin to Webcast Discussion of Presented Data on Monday, December 14, 2020 at 8:00 a.m., Eastern Standard TimeDUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 12, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN)...

Continue reading

UPS To Support Distribution Of Approved Vaccine As Part Of Operation Warp Speed

ATLANTA, Dec. 12, 2020 (GLOBE NEWSWIRE) —Deployments began after federal mandate to distribute therapies within 24 hours of emergency use authorization.UPS to help transport the initial Pfizer-BioNTech COVID-19 vaccine doses to support vaccinations of healthcare workers.UPS (NYSE:UPS) today announced its involvement and full support of distribution efforts for Pfizer-BioNTech’s COVID-19 vaccine as part of Operation Warp Speed. Pfizer’s and BioNTech’s vaccine, approved through a U.S. Food and Drug Administration emergency use authorization (EUA), is the first to be deployed in a months-long global race to develop safe vaccines to combat the spread of the COVID-19 virus.“Vaccine distribution is a key part of moving our world forward by delivering what matters,” says Carol Tomé, CEO of UPS. “We have dedicated and hardworking people...

Continue reading

Blockchain Technology: Discover Why Trade Community Worldwide is adopting it

Blockchain is a growing set of blocks linked together through cryptography. It is a modern database which stores information in the blocks and chained together. Each block contains a cryptographic hash of the previous block, a timestamp, and transaction data. One party to a transaction initiates the process by creating a block. This block is verified by thousands, perhaps millions of computers distributed around the net. The verified block is added to a chain, which is stored across the net, creating not just a unique record, but a unique record with a unique history. But why is the Trading world so fascinated with Blockchain?Transparency- Blockchain can drive increased supply chain transparency to help reduce fraud for high value commodities and goods. All transactions on the site are indelible, meaning no-one can attempt to manipulate,...

Continue reading

Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19

U.S. FDA authorizes COVID-19 mRNA vaccine for emergency use; companies are prepared to deliver first doses in the U.S. immediatelyPfizer and BioNTech previously announced an agreement with the U.S. Government to supply doses in 2020 & 2021In collaboration with Operation Warp Speed, Pfizer and BioNTech, as well as other vaccine companies are expected to deliver hundreds of millions of vaccine doses to Americans by the end of 2021Historic, science-driven efforts will seek to help bring an end to the most devastating pandemic in a centuryPfizer and BioNTech expect to file a Biologics License Application for possible full regulatory approval in 2021NEW YORK and MAINZ, GERMANY, December 11, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration (FDA) has authorized the...

Continue reading

Pfizer und BioNTech erhalten erste U.S.-Zulassung für COVID-19-Impfstoff

U.S. Food and Drug Administration erteilt Notfallzulassung für mRNA-basierten COVID-19-Impfstoff; Unternehmen sind darauf vorbereitet, sofort erste Impfstoffdosen in die USA auszuliefernPfizer und BioNTech haben zuvor eine Vereinbarung mit den Vereinigten Staaten über die Lieferung von Impfstoffdosen in den Jahren 2020 und 2021 bekannt gegebenIn Zusammenarbeit mit der U.S.-Regierung werden Pfizer und BioNTech sowie andere Unternehmen voraussichtlich bis Ende 2021 hunderte Millionen Impfdosen an Amerika liefernDie historischen, wissenschaftsgetriebenen Bemühungen werden dazu beitragen, der verheerendsten Pandemie seit 100 Jahren ein Ende zu setzenPfizer und BioNTech erwarten die Einreichung einer Beantragung zur biopharmazeutischen Anwendung (Biologics License Application) für eine mögliche volle behördliche Zulassung im Jahr 2021NEW YORK,...

Continue reading

Kaixin Auto Holdings Announces Appointment of New Auditor

BEIJING, Dec. 11, 2020 (GLOBE NEWSWIRE) — Kaixin Auto Holdings (“Kaixin” or the “Company”) (NASDAQ: KXIN) today announced the appointment of Marcum Bernstein & Pinchuk LLP (“MarcumBP”) as its independent registered public accounting firm, effective December 9, 2020.The appointment of MarcumBP was made after a careful and thorough evaluation process and has been approved by Kaixin’s board and audit committee.MarcumBP will replace KPMG Huazhen LLP (“KPMG”) as Kaixin’s independent registered public accounting firm. Kaixin’s decision to change its auditor was not the result of any disagreement between Kaixin and KPMG on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure.Safe Harbor StatementThis announcement contains forward-looking...

Continue reading

Heritage Cannabis Announces Change of Auditor

TORONTO, Dec. 11, 2020 (GLOBE NEWSWIRE) — HERITAGE CANNABIS HOLDINGS CORP. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company“) today announced that it has accepted the resignation of its auditor MNP LLP (“Former Auditor“) as of December 8, 2020 and that the board of directors of the Company has appointed Davidson & Company LLP (“Successor Auditor“) as the Company’s auditor effective December 8, 2020, until the next Annual General Meeting of the Company.There were no reservations or modified opinions in the Former Auditor’s audit reports for the Company. There are no “reportable events” (as the term is defined in National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102“)) between the Company and the Former Auditor.In accordance...

Continue reading

SmartCentres Real Estate Investment Trust Announces Redemption of 3.73% Series M and 2.876% Series Q Senior Unsecured Debentures

NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICESTORONTO, Dec. 11, 2020 (GLOBE NEWSWIRE) — SmartCentres Real Estate Investment Trust (“SmartCentres” or the “Trust”) (TSX:SRU.UN) announced today that it is issuing notices of redemption to holders of its 3.73% Series M senior unsecured debentures due July 22, 2022 (the “Series M Debentures”) and 2.876% Series Q senior unsecured debentures due March 21, 2022 (the “Series Q Debentures”, and together with the Series M Debentures, the “Debentures”), representing a redemption in full of all of the currently outstanding Series M Debentures and Series Q Debentures. The Debentures will be redeemed on January 11, 2021 (the “Redemption Date”), in accordance with their respective terms. The Series M Debentures will be redeemed at a total redemption price of $1,046.86...

Continue reading

Kraig Biocraft Laboratories Secures Bridge Funding and Files to Become Fully Reporting Company

ANN ARBOR, Mich., Dec. 11, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announced today that it has secured $950,000 in bridge financing and simultaneously filed with the SEC to become a mandatory, fully reporting company. Today the Company filed a Form 8-A to become fully reporting issuer. This financing will also make a significant contribution to that effort.“While being a voluntary filer, Kraig has been committed to meeting all SEC filing and reporting standards. Our election to now formalize these reporting responsibilities is evidence of our commitment to full operational transparency and growth,” said CEO and Founder, Kim Thompson. “The bridge financing will be used to continue scaling up our recombinant spider silk production and for other purposes related to the near...

Continue reading

Ziopharm Comments on Delay of WaterMill’s Stated Consent Deadline

Ziopharm Recommends Shareholders Return the GREEN Consent Revocation CardBOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent Solicitation”) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, “WaterMill”) following the delay of the original December 11 deadline set by WaterMill for Ziopharm shareholders to deliver written consents in support of the Consent Solicitation. Ziopharm continues to strongly recommend shareholders sign and return the Company’s GREEN Consent Revocation Card.The statement is as follows:“We have been informed that WaterMill has requested to delay the voting deadline until December 15, a clear sign that it does...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.